"Would value-based pricing of branded pharmaceuticals achieve the right price for optimal innovation incentives?" The right price for a branded pharma...
Read moreCEVR is thrilled to introduce the 2022 cohort of the Tufts-CEVR CEA Registry Summer Fellowship program, which is supported by the Gordon & Betty M...
Read moreDate: May 24, 2022 Rachel Breslau (RB): How did you get involved in health economics and outcomes research? Paige Lin (PL): I actually wanted to be a...
Read morePandya A, Paulden M, Zhu J, Lavelle TA, Hammitt J. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates. Med Decis Making. 2022 May 7:272989X221097106. doi: 10.1177/0272989X221097106. Epub ahead of print. PMID: 35531945.
Panzer A, Margaretos N, Bridger N, Osani M, Lai R, Chambers J. Patients’ access to 2018 FDA-approved drugs 1 year post approval. The American Journal of Managed Care, April 2022, Volume 28, Issue 4
Hlávka, J.P., Lavelle, T.A., Neumann, P.J. et al. Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers. PharmacoEconomics (2022). https://doi.org/10.1007/s40273-022-01150-w
Lavelle TA, Feng X, Keisler M, Cohen JT, Neumann PJ, Prichard D, Schroeder BE, Salyakina D, Espinal PS, Weidner SB, Maron JL, Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions, Genetics in Medicine, 2022, , ISSN 1098-3600, https://doi.org/10.1016/j.gim.2022.03.005.
Podolsky M, Present I, Neumann PJ, Kim DD, A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-health Impacts and Distributional Issues, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.02.003.
Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD, The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.01.025.
Neumann PJ, Garrison LP, Willke RJ. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health. 2022 March 9. DOI:https://doi.org/10.1016/j.jval.2022.01.010
Margaretos NM, Bawa K, Engmann NJ, Chambers JD. Patients' access to rare neuromuscular disease therapies varies across US private insurers. Orphanet J Rare Dis. 2022 Feb 5;17(1):36. doi: 10.1186/s13023-022-02182-3.
The Certainty Of Uncertainty In Health Technology Assessment, Health Affairs Forefront, January 26, 2022. DOI: 10.1377/forefront.20220125.37540
Medicare’s Aducanumab Decision Highlights Needed Reforms To FDA And CMS Regulatory Pathways, Health Affairs Forefront, January 25, 2022. DOI: 10.1377/forefront.20220121.566837
Ma, S., Lavelle, T.A., Ollendorf, D.A. et al. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries. Appl Health Econ Health Policy (2022). https://doi.org/10.1007/s40258-021-00711-y
Mulé C, Sliwinski, SK, Israel R, Lavelle TA, Developmental Behavioral Pediatrician Perspectives on Decision-Making in Early Treatment Planning for Children with Autism Spectrum Disorder, Journal of Developmental & Behavioral Pediatrics: October 12, 2021 - Volume - Issue - doi: 10.1097/DBP.0000000000001002
Chambers, J.D., Silver, M.C., Berklein, F.C. et al. Are Medical Devices Cost-Effective?. Appl Health Econ Health Policy (2021). https://doi.org/10.1007/s40258-021-00698-6
Hendrix N, Kim DD, Patel KS, Devine B. Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Med Decis Making. 2021 Apr;41(3):366-372. doi: 10.1177/0272989X20985821. Epub 2021 Jan 15. PMID: 33451278; PMCID: PMC7987800.
Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? Pharmacoeconomics. 2021 Oct 26. doi: 10.1007/s40273-021-01096-5
Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.
Meet the CEVR TeamOur comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.
The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.
View RegistryThe GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.
View RegistryThe Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.
View Database